The decision to enter bankruptcy is part of a broader restructuring at Avadel Pharmaceuticals, its parent company. Avadel Specialty is solely responsible for the production of the nighttime urination drug, Noctiva.
The specialty drugmaker plans to sell off its assets and wind down its business, according to the declaration filed in a Delaware Bankruptcy Court.
Advadel listed assets of $79.7 million and debts of $167.4 million, according to The Wall Street Journal.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.